Entecavir for Chronic Hepatitis B in Hepatocellular Carcinoma Patients Underwent Radiofrequency Ablation Therapy
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Persistent replication of HBV (47-55%) is frequently found in patients with HCC, which in
turn leads to deterioration of liver reserve. Moreover, a large proportion of HCC patients
who underwent curative therapy died from progressive liver decompensation rather than
recurrence of cancer. It had been proved that anti-viral therapy for hepatitis C virus
(HCV)-related HCC patients could reduce the rate of tumor recurrence after surgical
resection.
This is a prospective study to evaluate the efficacy of ETV therapy in chronic hepatitis B
patients after receiving RFA therapy for HCC.